OTCMKTS:AITB - AIT Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $5.00 +0.01 (+0.20 %) (As of 05/23/2019 04:00 PM ET)Previous Close$4.99Today's Range$4.85 - $5.2052-Week Range$2.79 - $6.25Volume44,000 shsAverage Volume17,673 shsMarket Capitalization$44.65 millionP/E RatioN/ADividend YieldN/ABeta-0.31 ProfileAnalyst RatingsChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email AIT Therapeutics, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria. The company was founded in 2011 and is based in Garden City, New York. Receive AITB News and Ratings via Email Sign-up to receive the latest news and ratings for AITB and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:AITB Previous Symbol CUSIPN/A CIKN/A Webhttp://www.ait-therapeutics.com/ Phone972-8684-3313Debt Debt-to-Equity RatioN/A Current Ratio2.17 Quick Ratio2.17Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($3.01) Net Income$-18,040,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-100.76%Miscellaneous Employees10 Outstanding Shares8,929,000Market Cap$44.65 million Next Earnings Date6/13/2019 (Estimated) OptionableNot Optionable AIT Therapeutics (OTCMKTS:AITB) Frequently Asked Questions What is AIT Therapeutics' stock symbol? AIT Therapeutics trades on the OTCMKTS under the ticker symbol "AITB." When is AIT Therapeutics' next earnings date? AIT Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, June 13th 2019. View Earnings Estimates for AIT Therapeutics. Has AIT Therapeutics been receiving favorable news coverage? News articles about AITB stock have trended somewhat negative recently, InfoTrie reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. AIT Therapeutics earned a news sentiment score of -1.7 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near future. Who are some of AIT Therapeutics' key competitors? Some companies that are related to AIT Therapeutics include Endologix (ELGX), T2 Biosystems (TTOO), iCAD (ICAD), RenovaCare (RCAR), Sensus Healthcare (SRTS), Apollo Endosurgery (APEN), Nuvectra (NVTR), Motus GI (MOTS), CAS Medical Systems (CASM), STRATA Skin Sciences (SSKN), Repro-Med Systems (REPR), RA Medical Systems (RMED), Titan Medical (TMDI), Invo Bioscience (IVOB) and Pro-Dex (PDEX). What other stocks do shareholders of AIT Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other AIT Therapeutics investors own include Allena Pharmaceuticals (ALNA), Harvard Bioscience (HBIO), MediciNova (MNOV), Obseva (OBSV), Pieris Pharmaceuticals (PIRS), Zogenix (ZGNX), Anthera Pharmaceuticals (ANTH), Apellis Pharmaceuticals (APLS), Athersys (ATHX) and Cerecor (CERC). Who are AIT Therapeutics' key executives? AIT Therapeutics' management team includes the folowing people: Mr. Steven Adam Lisi, CEO & Chairman (Age 48)Mr. Amir Avniel, Co-Founder, Pres, COO & Director (Age 45)Mr. Douglas J. Beck, Chief Financial Officer (Age 58)Prof. Asher Tal M.D., Sr. VP of Clinical Research & Member of Scientific Advisory BoardDr. Giora Davidai M.D., Chief Medical Officer How do I buy shares of AIT Therapeutics? Shares of AITB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is AIT Therapeutics' stock price today? One share of AITB stock can currently be purchased for approximately $5.00. How big of a company is AIT Therapeutics? AIT Therapeutics has a market capitalization of $44.65 million. The company earns $-18,040,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. AIT Therapeutics employs 10 workers across the globe. What is AIT Therapeutics' official website? The official website for AIT Therapeutics is http://www.ait-therapeutics.com/. How can I contact AIT Therapeutics? AIT Therapeutics' mailing address is 2 ILAN RAMON SCIENCE PARK, NESS ZIONA L3, 7403635. The company can be reached via phone at 972-8684-3313. MarketBeat Community Rating for AIT Therapeutics (OTCMKTS AITB)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 69 (Vote Outperform)Underperform Votes: 85 (Vote Underperform)Total Votes: 154MarketBeat's community ratings are surveys of what our community members think about AIT Therapeutics and other stocks. Vote "Outperform" if you believe AITB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AITB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/23/2019 by MarketBeat.com StaffFeatured Article: Trade Deficit Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.